🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

UK pre-market stocks update – AstraZeneca, Playtech, Ocado, Covid Update

Published 05/01/2022, 07:22
Updated 05/01/2022, 07:23
© Reuters
GBP/USD
-
EUR/GBP
-
IHG
-
FERG
-
AZN
-
LSEG
-
OXB
-
DX
-
UK100
-
PTEC
-
OCDO
-
SBAC
-
BTC/USD
-
AAF
-

By Samuel Indyk

Investing.com – At 07:17GMT, FTSE 100 futures are trading lower by 0.2% at 7422.

In FX markets, GBP/USD is trading at 1.3539, EUR/GBP is trading at 0.8345. The US Dollar Index is down 0.1%.

Bitcoin is trading at $46,433.

Today’s calendar highlights include Eurozone Services PMI, Canadian Building Permits, US Services PMI, Crude Oil Inventories, FOMC Meeting Minutes.

Coronavirus

UK Prime Minister Boris Johnson said there was a “good chance” he would not impose new coronavirus restrictions for England despite a surge in cases. Johnson added that parts of the NHS could feel “temporarily overwhelmed” due to the spread of Omicron. He also announced plans for 100,000 critical workers – including food processing and border force - to take daily tests.

Stocks

AstraZeneca (LON:AZN) - AstraZeneca has completed the transfer of its global rights to Eklira and Duaklir to Covis Pharma. AstraZeneca received a payment of $270 million from Covis Pharma and will also receive payments in respect of certain ongoing development costs related to the medicines.

Playtech (LON:PTEC) - Intends to adjourn the Court and General Meetings relating to the offer for Playtech by Aristocrat Leisure Limited, previously scheduled for 12 January 2022, to the new date of 2 February 2022. Playtech and JKO Play Limited have requested the Panel set a revised deadline, aligned to this new date for the Shareholder Meetings, by which JKO must clarify its intentions in relation to Playtech. Previously, Playtech had agreed to a takeover by Aristocrat. JKO made a preliminary approach for Playtech and talks are “progressing”.

Oxford BioMedica (LON:OXB) - Signed a new License and Supply Agreement with Cabaletta Bio granting Cabaletta Bio a non-exclusive license to Oxford Biomedica’s LentiVector platform for its application in Cabaletta Bio’s leading Chimeric AutoAntibody Receptor (CAAR) T programme, DSG3-CAART. Financial arrangements of this agreement are in line with comparable deals the Group has previously secured.

Airtel Africa (LON:AAF) - Closed first transaction to sell its telecommunications tower assets in Tanzania to a joint venture company owned by a wholly-owned subsidiary of SBA Communications Corporation (NASDAQ:SBAC). The gross consideration for the transaction will be $176.1 million.

Ocado (LON:OCDO) - Upgraded to buy from hold by Berenberg.

London Stock Exchange Group (LON:LSEG) - Upgraded to buy from neutral at Citi.

Ferguson (LON:FERG) - Upgraded to buy from hold by Berenberg.

InterContinental Hotels Group (LON:IHG) - Upgraded to buy from neutral by UBS.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.